



Annual Reporting SOP  
R&D GCP SOP 10 Version 5, 26.06.2024

<b>Department</b>	Research & Development
<b>Title of SOP</b>	<b>Annual reporting SOP</b>
<b>SOP reference no:</b>	R&D GCP SOP 10
<b>Authors:</b>	J H Pacynko
<b>Reviewed by</b>	J Illingworth and S Moffat
<b>Current version number and date:</b>	Version 5, 26.06.2024
<b>Next review date:</b>	26.06.2027
<b>Target audience:</b>	Research, pharmacy and R&D staff
<b>Distribution:</b>	HUTH R&D internet Click on GCP SOPs for HUTH-sponsored CTIMPs <a href="https://www.hey.nhs.uk/research/researchers/gcp-sops-for-hey-sponsored-ctimps/">https://www.hey.nhs.uk/research/researchers/gcp-sops-for-hey-sponsored-ctimps/</a>
<b>When this document is viewed as a paper copy, the reader is responsible for checking that it is the most recent version.</b>	
<p>© Hull University Teaching Hospitals NHS Trust 2021 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of Hull University Teaching Hospitals NHS Trust R&amp;D department.</p>	

Signed copy kept in RDI Department

Authorized by		Sign	Date
<b>R&amp;D Director</b>	Professor Thozhukat Sathyapalan		26/6/2024
<b>R&amp;D Manager</b>	James Illingworth		26/6/2024

## Annual Reporting SOP

R&amp;D GCP SOP 10 Version 5, 26.06.2024

This page details the version history and the main changes made for each new version.  
The new changes are in red font.

Version Log		
Version number and date	Author	Details of significant changes
Version 1, 06.11.12	J Pacynko and J Illingworth	Original SOP approved by R&D Committee on 01.11.12
Version 2, 31.03.16	H L Bexhell	Links checked New wording is in red font
Version 3, 18.03.19	J Pacynko	For single-site Type A trials, submitted under the Notification Scheme, the APR will now be used to submit annual safety updates to the MHRA and REC. Multi-site Type A and Type B trials will continue to use the DSUR.
Version 4, 19.03.21	S Moffat	In 3.7 and 4.12 the addition of saving a scanned copy of the Annual Progress Report and DSUR respectively to the eTMF or the eSSF.  Addition of point 4.14 A CTIMPs Safety Report Form must be completed and sent with the DSUR to REC. This form can be found on the HRA website <a href="https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/safety-reporting/">https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/safety-reporting/</a>
Version 5, 26.06.2024	L Cox	New wording is in red Amendment of wording from R&D to RDI throughout the SOP. Amendment of wording from REC Manager to the REC throughout the SOP.  In 1.1 the addition of HRA guidance in terms of when an APR is due for a clinical trial. New guidance from the HRA confirms that there are specific requirements for when an APR is required for a clinical trial. In 1.6 the addition of when a trial has been submitted through CWOW (Combined Review) process  In 1.7 the addition of the cost to now submitted an APR or DSUR as per HRA guidelines  In 4.1 amendment from EudraCT number to IRAS Number, as well as the addition of 'as well as a receipt confirming the fee has been paid'.

## Annual Reporting SOP

R&amp;D GCP SOP 10 Version 5, 26.06.2024

Section no.	Contents	Page no.
1	Background and Purpose	4
2	Who should use this SOP	4
3	Annual progress reporting	5
4	Annual safety reporting	5
5	Implementation	6

Please note for definitions of acronyms refer to Appendix 1 of Management of SOPs. Refer to Appendix 2 of Management of SOPs for the standards to which clinical trials that investigate the safety and/or efficacy of a medicinal product are conducted.

All the R&D GCP SOPs are available at:

<https://www.hey.nhs.uk/research/researchers/gcp-sops-for-hey-sponsored-ctimps/>

## 1 Background and purpose

1.1 NHS Research Ethics Committees (RECs) are required to monitor research that has received a favourable opinion. A progress report should be submitted by the Chief/Principal Investigator to the REC, which gave the favourable opinion, one year after the date on which the favourable opinion was given. Annual progress reports (APR) should be submitted thereafter until the end of the study. **However, progress reports are not required in the following instances:**

- if the study is expected to run for less than two years in duration
- if the study received a proportionate review
- if the study received a favourable ethics opinion from a REC in England or Wales.

1.2 In addition, the Medicines and Healthcare products Regulatory Agency (MHRA) require a safety report to be sent to the MHRA and REC once a year throughout the clinical trial. The annual safety report should take into account all new available safety information received during the reporting period.

1.3 For single-site Type A trials, authorised under the MHRA's Notification Scheme, the APR will also be used to submit annual safety updates to the MHRA and REC.

1.4 For multi-site Type A and Type B trials the MHRA's annual safety report will be the Development Safety Update Report (DSUR).

**Annual Reporting SOP**R&D GCP SOP 10 **Version 5, 26.06.2024**

- 1.5 The responsibility to complete and submit APRs and DSURs is delegated to the Chief/Principal Investigator (CI/PI) in the Formal Agreement signed by Investigator and Sponsor before RDI approval is given. The RDI Monitor will remind the CI/PI to complete the APR and DSUR when due and will help with completion and submission.
- 1.6 If the clinical trial (CTIMP) has gone through the Combined Review Process then the APR and DSUR must be submitted via the IRAS (<https://myresearchproject.org.uk/CWOW>) platform only.
- 1.7 The cost to submit an APR or a DSUR is currently £248.00. From the 1<sup>st</sup> June 2024, these payments need to be made online. Guidance for this can be found here [https://products.payments.service.gov.uk/pay/abbc9729dc244d2c82b02e25420454f8?\\_ga=2.165827070.1119410353.1718615281-538129580.1717657388](https://products.payments.service.gov.uk/pay/abbc9729dc244d2c82b02e25420454f8?_ga=2.165827070.1119410353.1718615281-538129580.1717657388). The MHRA ask that payment for the DSUR is made prior to submission and evidence of the payment is submitted with the DSUR. Payment should be requested by HUTH RDI QA to the RDI Finance manager to be paid for by the departmental credit card (other payment options are satisfactory to the discretion of the RDI Finance manager).
- 1.8 This SOP describes how to produce and submit the APR and DSUR.

## 2 Who should use this SOP

2.1 This SOP should be used by:

- All research staff involved with HUTH-sponsored CTIMPs – Chief/Principal Investigator, co-investigators, research nurses, clinical trial assistants, trial managers, clinical trial co-ordinators, data managers, administrators etc.
- Clinical trials pharmacy staff – technicians and pharmacists.
- All HUTH RDI staff who manage the sponsorship of HUTH-sponsored CTIMPs.
- Research staff involved with clinical trials sponsored by an external organisation where the sponsor has no SOP for safety reporting. HUTH RDI SOPs are defaulted to in this case.

## 3 Annual progress reporting

- 3.1 The first APR is due one year from the date of the REC favourable opinion for the study. APRs are then due on the same date each consecutive year for the duration of the study.
- 3.2 The APR link and reminders of what to include in the form are available from the RDI Monitor or QA Manager. This is Working Instruction 21 available on the ClinicalGov Y Drive in Research\GCP SOPs & forms\Working instructions.
- 3.3 The form title is 'Annual progress report form for clinical trials of investigational medicinal products (CTIMPs)'.
- 3.4 The APR is a short form and asks for up-to-date information on the start and end date of the study, the number of sites involved, the number of patients recruited, safety reports, amendments and serious breaches.
- 3.5 The RDI monitor will help with the completion and submission of the APR. If the trial is being managed by a Clinical Trials Unit, the CTU will help with the completion and submission.

**Annual Reporting SOP**R&D GCP SOP 10 **Version 5, 26.06.2024**

3.6 The APR needs to be completed and signed by the CI/PI. A copy should be sent to the REC used for the study **within 30 days** of the end of the reporting period

3.7 The original, signed APR should be filed in the REC section of a paper Trial Master File or a scanned copy saved in the electronic TMF or SSF.

## 4 Annual safety reporting

4.1 For single-site trials, authorised under the MHRA's Notification Scheme (Type A trials), the Annual Progress Report will be used to report the safety information. A covering letter will need to be submitted which includes the **IRAS number** and CTA reference number and that the APR is in place of a full DSUR, **as well as a receipt confirming the fee has been paid**. A list of all the SARs will need to be added to section 6 of the APR.

4.2 For Type B trials and multi-site Type A trials, the Development Safety Update Report (DSUR) will be completed. The **RDI** monitor will complete the administrative parts of the DSUR and then send to the CI/PI for completion of the clinical safety information and assessments. The **RDI** monitor will submit the DSUR to the MHRA and REC. If the trial is being managed by a Clinical Trials Unit, the CTU will submit the DSUR.

4.3 The Reference Safety Information will need to be reviewed for updates annually at the time the APR or DSUR is completed. This check will be documented in the APR or DSUR.

4.4 The first DSUR is due one year from the date of the MHRA Clinical Trial Authorisation for the study. DSURs are then due on the same date each consecutive year for the duration of the study.

4.5 The DSUR must be submitted to the MHRA **within 60 days** from the date it was due. During MHRA inspections the inspectors check whether timelines have been respected and if not class this as a 'finding'. If there is a large volume of findings from an inspection, this could be classed as a critical finding which involves re-inspection of the Trust.

4.6 If there is a failure to submit the DSUR within 60 days then this will be escalated to the **RDI** Director who will raise the issue with the CI/PI to take appropriate action.

4.7 A copy of the signed DSUR should be sent to the REC responsible for the study at the same time as submitting to the MHRA.

4.8 The aim of the DSUR is to describe concisely all new safety information relevant for the clinical trial and to assess the safety of subjects included in these studies.

4.9 The DSUR should include the following:

- A covering letter.
- An overall safety assessment with an evaluation of the risk: benefit and a summary of the important risks.
- A line listing of SARs (including SUSARs) during the reporting period (if any).
- A cumulative summary tabulation of all SAEs since the start of the study (if any).

**Annual Reporting SOP**R&D GCP SOP 10 **Version 5, 26.06.2024**

- 4.10 A template for the DSUR and guidance on how to complete the DSUR is available from the R&D Monitor or QA Manager. This is Working Instruction 22 available on the \\hri\_data3\clinicalgov\Research\GCP SOPs & forms\SOPs & WIs.
- 4.11 It is very much recommended that the guidance is used because there are many sections of the DSUR that are not relevant for Trust-sponsored CTIMPs and the guide indicates those sections.
- 4.12 The original, signed DSUR should be filed in the MHRA section of a paper Trial Master File or a scanned copy saved in the electronic TMF or SSF.
- 4.13 A copy of the signed DSUR should be sent to the **RDI** Monitor or QA Manager who will submit the DSUR to the MHRA and email a copy to the REC.
- 4.14 A CTIMPs Safety Report Form must be completed and sent with the DSUR to REC. This form can be found on the HRA website <https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/safety-reporting/>

**5 Implementation**

- 5.1 Implementation of this SOP will conform to the process outlined in [R&D SOP 01 Management of SOPs](#).